PCSK9 and Hypercholesterolemia: Two fully human anti-PCSK9 monoclonal antibodies (MAbs), alirocumab (SAR236553/REGN727 from Regeneron Pharmaceuticals/Sanofi) and evolocumab (AMG145 by Amgen), are currently approved for the treatment of hypercholesterolemia by the US Food and Drug Administration and European Medicines Agency.